Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is evaluating the efficacy and safety of Deucravacitinib in adults with active Sjögren’s Syndrome. Officially titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’, the study aims to assess the therapeutic potential of Deucravacitinib, a promising drug candidate, in treating this chronic autoimmune condition.
The study is testing two doses of Deucravacitinib, an experimental drug, against a placebo. Deucravacitinib is designed to target specific pathways involved in the inflammatory process, potentially offering a new treatment option for patients with Sjögren’s Syndrome.
This Phase 3 study is interventional, with a randomized, parallel assignment model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on September 11, 2023, and is currently recruiting participants. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating potential market impacts.
The ongoing study could significantly influence Bristol-Myers Squibb’s stock performance, especially if Deucravacitinib proves effective. Positive results could enhance investor confidence and position the company favorably against competitors in the autoimmune treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.